Diosgenin targets Akt-mediated prosurvival signaling in human breast cancer cells

Sowmyalakshmi Srinivasan, Srinivas Koduru, Raj Kumar, Guhan Venguswamy, Natasha Kyprianou, Chendil Damodaran

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

In recent years, Akt signaling has gained recognition for its functional role in more aggressive, therapy-resistant malignancies. As it is frequently constitutively active in cancer cells, several drugs are being investigated for their ability to inhibit Akt signaling. The purpose of this study is to determine effect of diosgenin (fenugreek), a dietary compound on Akt signaling and its downstream targets on estrogen receptor positive (ER+) and estrogen receptor negative (ER-) breast cancer (BCa) cells. Diosgenin inhibits pAkt expression and Akt kinase activity without affecting PI3 kinase levels, resulting in the inhibition of its downstream targets, NFκB, Bcl-2, survivin and XIAP. The Raf/MEK/ERK pathway, another functional downstream target of Akt, was inhibited by diosgenin in ER+ but not in ER- BCa cells. Additionally, we found that diosgenin caused G1 cell cycle arrest by downregulating cyclin D1, cdk-2 and cdk-4 expression in both ER+ and ER- BCa cells resulting in the inhibition of cell proliferation and induction of apoptosis. Interestingly, no significant toxicity was seen in the normal breast epithelial cells (MCF-10A) following treatment with diosgenin. Additionally, in vivo tumor studies indicate diosgenin significantly inhibits tumor growth in both MCF-7 and MDA-231 xenografts in nude mice. Thus, these results suggest that diosgenin might prove to be a potential chemotherapeutic agent for the treatment of BCa.

Original languageEnglish (US)
Pages (from-to)961-967
Number of pages7
JournalInternational Journal of Cancer
Volume125
Issue number4
DOIs
StatePublished - Aug 15 2009

Fingerprint

Diosgenin
Breast Neoplasms
Estrogen Receptors
Neoplasms
Trigonella
G1 Phase Cell Cycle Checkpoints
MAP Kinase Signaling System
Cyclin D1
Phosphatidylinositol 3-Kinases
Heterografts
Nude Mice
Breast
Phosphotransferases
Down-Regulation
Epithelial Cells
Cell Proliferation
Apoptosis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Srinivasan, Sowmyalakshmi ; Koduru, Srinivas ; Kumar, Raj ; Venguswamy, Guhan ; Kyprianou, Natasha ; Damodaran, Chendil. / Diosgenin targets Akt-mediated prosurvival signaling in human breast cancer cells. In: International Journal of Cancer. 2009 ; Vol. 125, No. 4. pp. 961-967.
@article{abc963423d604c7db7a94510f7a6ad0d,
title = "Diosgenin targets Akt-mediated prosurvival signaling in human breast cancer cells",
abstract = "In recent years, Akt signaling has gained recognition for its functional role in more aggressive, therapy-resistant malignancies. As it is frequently constitutively active in cancer cells, several drugs are being investigated for their ability to inhibit Akt signaling. The purpose of this study is to determine effect of diosgenin (fenugreek), a dietary compound on Akt signaling and its downstream targets on estrogen receptor positive (ER+) and estrogen receptor negative (ER-) breast cancer (BCa) cells. Diosgenin inhibits pAkt expression and Akt kinase activity without affecting PI3 kinase levels, resulting in the inhibition of its downstream targets, NFκB, Bcl-2, survivin and XIAP. The Raf/MEK/ERK pathway, another functional downstream target of Akt, was inhibited by diosgenin in ER+ but not in ER- BCa cells. Additionally, we found that diosgenin caused G1 cell cycle arrest by downregulating cyclin D1, cdk-2 and cdk-4 expression in both ER+ and ER- BCa cells resulting in the inhibition of cell proliferation and induction of apoptosis. Interestingly, no significant toxicity was seen in the normal breast epithelial cells (MCF-10A) following treatment with diosgenin. Additionally, in vivo tumor studies indicate diosgenin significantly inhibits tumor growth in both MCF-7 and MDA-231 xenografts in nude mice. Thus, these results suggest that diosgenin might prove to be a potential chemotherapeutic agent for the treatment of BCa.",
author = "Sowmyalakshmi Srinivasan and Srinivas Koduru and Raj Kumar and Guhan Venguswamy and Natasha Kyprianou and Chendil Damodaran",
year = "2009",
month = "8",
day = "15",
doi = "10.1002/ijc.24419",
language = "English (US)",
volume = "125",
pages = "961--967",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

Srinivasan, S, Koduru, S, Kumar, R, Venguswamy, G, Kyprianou, N & Damodaran, C 2009, 'Diosgenin targets Akt-mediated prosurvival signaling in human breast cancer cells', International Journal of Cancer, vol. 125, no. 4, pp. 961-967. https://doi.org/10.1002/ijc.24419

Diosgenin targets Akt-mediated prosurvival signaling in human breast cancer cells. / Srinivasan, Sowmyalakshmi; Koduru, Srinivas; Kumar, Raj; Venguswamy, Guhan; Kyprianou, Natasha; Damodaran, Chendil.

In: International Journal of Cancer, Vol. 125, No. 4, 15.08.2009, p. 961-967.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Diosgenin targets Akt-mediated prosurvival signaling in human breast cancer cells

AU - Srinivasan, Sowmyalakshmi

AU - Koduru, Srinivas

AU - Kumar, Raj

AU - Venguswamy, Guhan

AU - Kyprianou, Natasha

AU - Damodaran, Chendil

PY - 2009/8/15

Y1 - 2009/8/15

N2 - In recent years, Akt signaling has gained recognition for its functional role in more aggressive, therapy-resistant malignancies. As it is frequently constitutively active in cancer cells, several drugs are being investigated for their ability to inhibit Akt signaling. The purpose of this study is to determine effect of diosgenin (fenugreek), a dietary compound on Akt signaling and its downstream targets on estrogen receptor positive (ER+) and estrogen receptor negative (ER-) breast cancer (BCa) cells. Diosgenin inhibits pAkt expression and Akt kinase activity without affecting PI3 kinase levels, resulting in the inhibition of its downstream targets, NFκB, Bcl-2, survivin and XIAP. The Raf/MEK/ERK pathway, another functional downstream target of Akt, was inhibited by diosgenin in ER+ but not in ER- BCa cells. Additionally, we found that diosgenin caused G1 cell cycle arrest by downregulating cyclin D1, cdk-2 and cdk-4 expression in both ER+ and ER- BCa cells resulting in the inhibition of cell proliferation and induction of apoptosis. Interestingly, no significant toxicity was seen in the normal breast epithelial cells (MCF-10A) following treatment with diosgenin. Additionally, in vivo tumor studies indicate diosgenin significantly inhibits tumor growth in both MCF-7 and MDA-231 xenografts in nude mice. Thus, these results suggest that diosgenin might prove to be a potential chemotherapeutic agent for the treatment of BCa.

AB - In recent years, Akt signaling has gained recognition for its functional role in more aggressive, therapy-resistant malignancies. As it is frequently constitutively active in cancer cells, several drugs are being investigated for their ability to inhibit Akt signaling. The purpose of this study is to determine effect of diosgenin (fenugreek), a dietary compound on Akt signaling and its downstream targets on estrogen receptor positive (ER+) and estrogen receptor negative (ER-) breast cancer (BCa) cells. Diosgenin inhibits pAkt expression and Akt kinase activity without affecting PI3 kinase levels, resulting in the inhibition of its downstream targets, NFκB, Bcl-2, survivin and XIAP. The Raf/MEK/ERK pathway, another functional downstream target of Akt, was inhibited by diosgenin in ER+ but not in ER- BCa cells. Additionally, we found that diosgenin caused G1 cell cycle arrest by downregulating cyclin D1, cdk-2 and cdk-4 expression in both ER+ and ER- BCa cells resulting in the inhibition of cell proliferation and induction of apoptosis. Interestingly, no significant toxicity was seen in the normal breast epithelial cells (MCF-10A) following treatment with diosgenin. Additionally, in vivo tumor studies indicate diosgenin significantly inhibits tumor growth in both MCF-7 and MDA-231 xenografts in nude mice. Thus, these results suggest that diosgenin might prove to be a potential chemotherapeutic agent for the treatment of BCa.

UR - http://www.scopus.com/inward/record.url?scp=67650067290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650067290&partnerID=8YFLogxK

U2 - 10.1002/ijc.24419

DO - 10.1002/ijc.24419

M3 - Article

C2 - 19384950

AN - SCOPUS:67650067290

VL - 125

SP - 961

EP - 967

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -